SAN DIEGO -- The investigational monoclonal antibody marstacimab reduced the rate of treated bleeds in patients with hemophilia A or B without inhibitors to factor VIII or factor IX, the phase III ...

Hemophilia B, also known as Christmas disease, is a bleeding disorder. Its characteristic feature is a deficiency of clotting factor IX. This is a protein present in the blood that helps with ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3, ...

With Pfizer having recently scored an approval for its tissue factor pathway inhibitor Hympavzi, Centessa Pharmaceuticals has decided that taking its own hemophilia B contender to market is not worth ...

In the ATLAS clinical development program, Qfitlia demonstrated low bleed rates across subgroups with as few as six injections a year. Key results include: Significant bleed reduction by 71% in ABR ...

A 70-year-old man undergoing a leg amputation was diagnosed with a rare combination of acquired hemophilia A and Factor XII ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go. Pfizer ...

Prophylaxis with efanesoctocog alfa, while reducing annualized bleeding rate by 77% compared with standard-care factor VIII in severe hemophilia A, is not cost-effective at current US pricing, ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. Meanwhile, PTC Therapeutics' troubled ...